Published 22 hours ago • loading... • Updated 18 hours ago

Edesa Biotech Announces Chief Financial Officer Transition

Summary by Financial Post

Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage pharmaceutical company. From August 2017 to August 2018, Mr. Weiler served as Vice President of Business Development at Biosyent Inc. Prior to that, he served in various roles at Cipher Pharmaceuticals Inc., inc…

7 Articles

All

Left

Center

Right

Inside Halton

+6 Reposted by 6 other sources

Lean Left

Edesa Biotech Announces Chief Financial Officer Transition

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr.…

22 hours ago·Halton Hills, Canada

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year